+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


  • PDF Icon


  • 11 Pages
  • December 2018
  • Region: Global
  • Citeline
  • ID: 4775103
Drug Overview
GSK-3 is a 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine, which also includes the conserved, unconjugated pneumococcal proteins dPly and PhtD. dPly is a thiol-dependent toxin, while PhtD is a protein which is exposed on the surface of intact bacteria, and vaccines based on these proteins have the potential to provide broader protection against pneumococcal disease.

Analyst Outlook
GSK-3’s (10-valent recombinant-conjugate pneumococcal vaccine; GlaxoSmithKline) novel vaccine approach and potential for broader coverage will make it a strong contender on the market, but it will face significant competition from Prevnar 13 (13-valent
pneumococcal conjugate vaccine; Pfizer), as well as pipeline vaccines V114 (15-valent pneumococcal conjugate vaccine; Merck & Co) and PF-06482077 (20-valent pneumococcal conjugate vaccine; Pfizer), which also aim to provide broader protection.

Table of Contents

Drug Overview
Product Profiles
GSK-3 : Pneumococcal vaccines

Table 1: GSK-3 drug profile
Table 2: Trials of GSK-3 for pneumococcal vaccination
Table 3: GSK-3 for pneumococcal vaccination – SWOT analysis